The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2026 | Lessons learned from a myeloma clinical case: the importance of bridging therapy in CAR-T
In this interview, Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, discusses a clinical case of a patient with relapsed/refractory (R/R) multiple myeloma (MM) receiving CAR T-cell therapy and highlights the lessons that can be learned from this case, namely the importance of sufficient bridging therapy in this setting. This interview took place at the EBMT-EHA 8th European CAR T-cell Meeting, held in Palma de Mallorca, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so I discussed the case of a patient who was actually not responding to any previous therapy, and then we decided to put him on a CAR T-cell therapy, and he finally, with no response to bridging therapy, infused the CAR T-cell product. The patient came into complete remission with MRD-negative imaging, so the best possible result. And unfortunately, the patient then developed a Parkinsonian-like syndrome...
Yeah, so I discussed the case of a patient who was actually not responding to any previous therapy, and then we decided to put him on a CAR T-cell therapy, and he finally, with no response to bridging therapy, infused the CAR T-cell product. The patient came into complete remission with MRD-negative imaging, so the best possible result. And unfortunately, the patient then developed a Parkinsonian-like syndrome. And I discussed that the bridging therapy is extremely important. We are increasingly learning that in patients who receive CAR T-cell therapy, it is extremely important that we increasingly learn that in patients who receive CAR T-cell therapy, it is extremely important to get control of the disease prior to CAR T-cell therapy. This improves the response quality after CAR T-cell therapy, prolongs the disease-free survival, and also reduces the toxicity. So the main message from this case was to try to approach the patient as sufficiently as possible prior to CAR T-cell therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
